The growth in the historic period can be attributed to increasing incidence of chronic kidney disease, rising chemotherapy-related anemia cases, expansion of dialysis treatment centers, clinical validation of recombinant erythropoietin, growth of injectable biologics manufacturing.
The growth in the forecast period can be attributed to increasing aging population with anemia risk, rising demand for long-term anemia therapies, expansion of biologic drug accessibility, growing focus on patient quality of life, increasing use of biosimilar-compatible treatment pathways. Major trends in the forecast period include increasing use of erythropoiesis-stimulating agents, growing demand for anemia management in ckd patients, rising adoption of biologic injectables, expansion of oncology-related anemia treatments, enhanced focus on hemoglobin optimization.
The rising prevalence of chronic kidney disease (CKD) is expected to support the growth of the Neorecormon market in the coming years. Chronic kidney disease is a progressive condition in which kidney function gradually declines, often causing anemia due to reduced erythropoietin production. The increase in CKD cases is driven by factors such as an aging population and lifestyle-related diseases. Neorecormon plays a vital role for individuals with CKD by managing anemia and improving quality of life as the disease progresses. For example, in June 2023, according to Kidney Research UK, a UK-based non-profit organization, approximately 7.2 million people in the UK were living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million were in advanced stages, while 3.9 million were in early stages. The number of people affected by CKD is projected to rise to 7.61 million by 2033. Therefore, the rising prevalence of CKD is driving the growth of the Neorecormon market.
The expanding aging population is anticipated to drive the Neorecormon market forward. Aging is a natural process characterized by a gradual decline in physiological functions, making individuals more susceptible to chronic conditions such as kidney disease and cancer, which often lead to anemia. The aging population is increasing due to healthcare advancements, longer life expectancy, and declining birth rates. Neorecormon, an erythropoiesis-stimulating agent (ESA), is essential for managing anemia by increasing red blood cell production, enhancing energy levels, and improving treatment outcomes for elderly patients. For example, in February 2025, according to the World Health Organization, a Switzerland-based international public health organization, global life expectancy at birth reached 73.3 years in 2024, and the number of people aged 60 and older worldwide is projected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the growing aging population is supporting the growth of the Neorecormon market.
The increase in healthcare expenditures is expected to contribute to the expansion of the Neorecormon market in the coming years. Healthcare expenditures encompass the total spending on medical services, products, and programs within a specified period at individual, community, national, or global levels. Rising healthcare expenditures are driven by the increasing prevalence of chronic diseases, an aging population, advancements in medical technology, and greater demand for advanced treatments and healthcare services. Higher healthcare spending improves access to treatments like Neorecormon by expanding insurance coverage, reducing patient costs, and supporting anemia management programs, fostering early diagnosis, wider adoption, and market growth, particularly in emerging economies. For instance, in May 2023, according to the Office for National Statistics, a UK-based statistics authority, healthcare expenditure in the UK reached approximately $367 billion (£292 billion) in 2023, reflecting a 5.6% increase. Additionally, long-term health and social care spending rose by 2.8% in real terms in 2022. Therefore, increasing healthcare expenditures are driving the growth of the Neorecormon market.
Major companies operating in the neorecormon market are F. Hoffmann-La Roche Ltd.
North America was the largest region in the neorecormon market in 2025. The regions covered in the neorecormon market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neorecormon market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the neorecormon market by increasing costs of imported biologic raw materials, recombinant protein processing equipment, cold-chain packaging, and sterile injection systems. Europe and North America are most affected due to cross-border sourcing of erythropoietin APIs and biologic excipients, while Asia-Pacific faces higher export-related manufacturing costs. These tariffs are elevating treatment costs and affecting hospital procurement budgets. However, they are also supporting localized biologics manufacturing, regional biopharmaceutical investments, and expanded domestic production of erythropoiesis-stimulating therapies.
The neorecormon market research report is one of a series of new reports that provides neorecormon market statistics, including neorecormon industry global market size, regional shares, competitors with a neorecormon market share, detailed neorecormon market segments, market trends and opportunities, and any further data you may need to thrive in the neorecormon industry. This neorecormon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Neorecormon is a biopharmaceutical drug used to treat anemia resulting from chronic kidney disease, chemotherapy, or other conditions that impair red blood cell production. It acts as an erythropoietin-stimulating agent, enhancing red blood cell formation to improve oxygen delivery throughout the body.
The primary formulations of Neorecormon include injectable solutions and prefilled syringes. Injectable solutions are administered directly into the body via a needle or syringe, and Neorecormon in this form is used to treat anemia in patients with chronic kidney disease by stimulating red blood cell production and improving oxygen transport. The indications include anemia due to chronic kidney disease, anemia in cancer patients, and anemia associated with other conditions. End users include adult and pediatric patients, with distribution through hospitals, specialty clinics, retail pharmacies, and online pharmacies.
The neorecormon market consists of sales of erythropoietin-stimulating agents in formulations such as vials, cartridges, and ampoules. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to increasing aging population with anemia risk, rising demand for long-term anemia therapies, expansion of biologic drug accessibility, growing focus on patient quality of life, increasing use of biosimilar-compatible treatment pathways. Major trends in the forecast period include increasing use of erythropoiesis-stimulating agents, growing demand for anemia management in ckd patients, rising adoption of biologic injectables, expansion of oncology-related anemia treatments, enhanced focus on hemoglobin optimization.
The rising prevalence of chronic kidney disease (CKD) is expected to support the growth of the Neorecormon market in the coming years. Chronic kidney disease is a progressive condition in which kidney function gradually declines, often causing anemia due to reduced erythropoietin production. The increase in CKD cases is driven by factors such as an aging population and lifestyle-related diseases. Neorecormon plays a vital role for individuals with CKD by managing anemia and improving quality of life as the disease progresses. For example, in June 2023, according to Kidney Research UK, a UK-based non-profit organization, approximately 7.2 million people in the UK were living with chronic kidney disease, representing over 10% of the population. Of these, 3.25 million were in advanced stages, while 3.9 million were in early stages. The number of people affected by CKD is projected to rise to 7.61 million by 2033. Therefore, the rising prevalence of CKD is driving the growth of the Neorecormon market.
The expanding aging population is anticipated to drive the Neorecormon market forward. Aging is a natural process characterized by a gradual decline in physiological functions, making individuals more susceptible to chronic conditions such as kidney disease and cancer, which often lead to anemia. The aging population is increasing due to healthcare advancements, longer life expectancy, and declining birth rates. Neorecormon, an erythropoiesis-stimulating agent (ESA), is essential for managing anemia by increasing red blood cell production, enhancing energy levels, and improving treatment outcomes for elderly patients. For example, in February 2025, according to the World Health Organization, a Switzerland-based international public health organization, global life expectancy at birth reached 73.3 years in 2024, and the number of people aged 60 and older worldwide is projected to rise from 1.1 billion in 2023 to 1.4 billion by 2030. Therefore, the growing aging population is supporting the growth of the Neorecormon market.
The increase in healthcare expenditures is expected to contribute to the expansion of the Neorecormon market in the coming years. Healthcare expenditures encompass the total spending on medical services, products, and programs within a specified period at individual, community, national, or global levels. Rising healthcare expenditures are driven by the increasing prevalence of chronic diseases, an aging population, advancements in medical technology, and greater demand for advanced treatments and healthcare services. Higher healthcare spending improves access to treatments like Neorecormon by expanding insurance coverage, reducing patient costs, and supporting anemia management programs, fostering early diagnosis, wider adoption, and market growth, particularly in emerging economies. For instance, in May 2023, according to the Office for National Statistics, a UK-based statistics authority, healthcare expenditure in the UK reached approximately $367 billion (£292 billion) in 2023, reflecting a 5.6% increase. Additionally, long-term health and social care spending rose by 2.8% in real terms in 2022. Therefore, increasing healthcare expenditures are driving the growth of the Neorecormon market.
Major companies operating in the neorecormon market are F. Hoffmann-La Roche Ltd.
North America was the largest region in the neorecormon market in 2025. The regions covered in the neorecormon market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neorecormon market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the neorecormon market by increasing costs of imported biologic raw materials, recombinant protein processing equipment, cold-chain packaging, and sterile injection systems. Europe and North America are most affected due to cross-border sourcing of erythropoietin APIs and biologic excipients, while Asia-Pacific faces higher export-related manufacturing costs. These tariffs are elevating treatment costs and affecting hospital procurement budgets. However, they are also supporting localized biologics manufacturing, regional biopharmaceutical investments, and expanded domestic production of erythropoiesis-stimulating therapies.
The neorecormon market research report is one of a series of new reports that provides neorecormon market statistics, including neorecormon industry global market size, regional shares, competitors with a neorecormon market share, detailed neorecormon market segments, market trends and opportunities, and any further data you may need to thrive in the neorecormon industry. This neorecormon market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Neorecormon is a biopharmaceutical drug used to treat anemia resulting from chronic kidney disease, chemotherapy, or other conditions that impair red blood cell production. It acts as an erythropoietin-stimulating agent, enhancing red blood cell formation to improve oxygen delivery throughout the body.
The primary formulations of Neorecormon include injectable solutions and prefilled syringes. Injectable solutions are administered directly into the body via a needle or syringe, and Neorecormon in this form is used to treat anemia in patients with chronic kidney disease by stimulating red blood cell production and improving oxygen transport. The indications include anemia due to chronic kidney disease, anemia in cancer patients, and anemia associated with other conditions. End users include adult and pediatric patients, with distribution through hospitals, specialty clinics, retail pharmacies, and online pharmacies.
The neorecormon market consists of sales of erythropoietin-stimulating agents in formulations such as vials, cartridges, and ampoules. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Neorecormon Market Characteristics
3. Neorecormon Market Supply Chain Analysis
4. Global Neorecormon Market Trends and Strategies
5. Neorecormon Market Analysis of End Use Industries
7. Global Neorecormon Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Neorecormon Total Addressable Market (TAM) Analysis for the Market
9. Neorecormon Market Segmentation
10. Neorecormon Market Regional and Country Analysis
11. Asia-Pacific Neorecormon Market
12. China Neorecormon Market
13. India Neorecormon Market
14. Japan Neorecormon Market
15. Australia Neorecormon Market
16. South Korea Neorecormon Market
17. Western Europe Neorecormon Market
18. UK Neorecormon Market
19. Germany Neorecormon Market
20. France Neorecormon Market
21. Eastern Europe Neorecormon Market
22. North America Neorecormon Market
23. USA Neorecormon Market
24. Canada Neorecormon Market
25. South America Neorecormon Market
26. Middle East Neorecormon Market
27. Africa Neorecormon Market
29. Neorecormon Market Competitive Landscape and Company Profiles
32. Neorecormon Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Neorecormon Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses neorecormon market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for neorecormon? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The neorecormon market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Formulation: Injectable Solution; Pre-Filled Syringes2) By Indication: Anemia Due To Chronic Kidney Disease (CKD); Anemia In Cancer Patients; Anemia Associated With Other Conditions
3) By End User Patients: Adult Patients; Pediatric Patients
4) By Distribution Channel: Hospitals; Specialty Clinics; Retail Pharmacies; Online Pharmacies
Companies Mentioned: F. Hoffmann-La Roche Ltd.
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Neorecormon market report include:- F. Hoffmann-La Roche Ltd.
